GlassScriptPhysician profile
Sayed A Hussain
NPI 1306948294
$1,046.20
in general payments reported to CMS, 2019-2025
15 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.59 · 2020: $12.62 · 2021: $23.86 · 2022: $198 · 2023: $572 · 2024: $39.90 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $242.74 | 2022-2023 | Puraply |
| Abbott Laboratories | $139.95 | 2023 | Jeti |
| Si-Bone, INC. | $137.35 | 2025 | |
| Janssen Biotech, INC. | $122.83 | 2022 | |
| Glaxosmithkline, LLC. | $117.46 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Baxter Healthcare | $65.92 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $52.31 | 2023 | |
| Lilly USA, LLC | $33.40 | 2023 | Mounjaro |
| Abbvie INC. | $27.31 | 2021-2022 | |
| Novo Nordisk INC | $25.35 | 2021-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $23.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.77 | 2023 | Xifaxan |
| Kci USA, INC. | $13.59 | 2019 | |
| Allergan, INC. | $12.62 | 2020 | |
| Phathom Pharmaceuticals, INC. | $8.82 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.